FDA Alerts Public to Counterfeit Ozempic Diabetes Drug

The FDA has issued a warning about counterfeit versions of Novo Nordisk's diabetes drug Ozempic that have been found in the drug supply chain. The agency has seized thousands of units and is currently testing the products to determine their identity, quality, and safety. The counterfeit injections pose a risk of infection due to the uncertainty of their sterility. The FDA has urged distributors, pharmacies, healthcare practitioners, and patients to check their supply and avoid using or selling units labeled with specific lot and serial numbers. Demand for Ozempic and its obesity counterpart, Wegovy, is exceeding supply, leading to restrictions on certain doses in the US market.